These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37975107)

  • 1. Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review.
    Ziamanesh F; Mohammadi M; Ebrahimpour S; Tabatabaei-Malazy O; Mosallanejad A; Larijani B
    J Diabetes Metab Disord; 2023 Dec; 22(2):1083-1094. PubMed ID: 37975107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
    Duseja A; Singh SP; Saraswat VA; Acharya SK; Chawla YK; Chowdhury S; Dhiman RK; Jayakumar RV; Madan K; Misra SP; Mishra H; Modi SK; Muruganathan A; Saboo B; Sahay R; Upadhyay R
    J Clin Exp Hepatol; 2015 Mar; 5(1):51-68. PubMed ID: 25941433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
    Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
    Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
    Sharma N; Chakole S; Wandile B
    Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
    Ore A; Akinloye OA
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-processed food consumption and non-alcoholic fatty liver disease, metabolic syndrome and insulin resistance: A systematic review.
    Grinshpan LS; Eilat-Adar S; Ivancovsky-Wajcman D; Kariv R; Gillon-Keren M; Zelber-Sagi S
    JHEP Rep; 2024 Jan; 6(1):100964. PubMed ID: 38234408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nonalcoholic fatty liver disease : Hepatic manifestations of metabolic syndrome].
    Roeb E
    Inn Med (Heidelb); 2023 Apr; 64(4):323-328. PubMed ID: 36580094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past.
    Ayonrinde OT
    JHEP Rep; 2021 Jun; 3(3):100261. PubMed ID: 34036255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations.
    Kumar R; Priyadarshi RN; Anand U
    J Clin Transl Hepatol; 2020 Mar; 8(1):76-86. PubMed ID: 32274348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
    Targher G; Rossini M; Lonardo A
    Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause.
    Robeva R; Mladenović D; Vesković M; Hrnčić D; Bjekić-Macut J; Stanojlović O; Livadas S; Yildiz BO; Macut D
    Maturitas; 2021 Sep; 151():22-30. PubMed ID: 34446275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.